CLISSA, CRISTINA
 Distribuzione geografica
Continente #
NA - Nord America 1266
EU - Europa 1226
AS - Asia 487
AF - Africa 114
SA - Sud America 2
Totale 3095
Nazione #
US - Stati Uniti d'America 1258
GB - Regno Unito 437
SE - Svezia 274
CN - Cina 195
VN - Vietnam 195
DE - Germania 137
IT - Italia 130
IN - India 69
RU - Federazione Russa 53
TG - Togo 46
FR - Francia 45
GR - Grecia 40
ZA - Sudafrica 34
NG - Nigeria 27
UA - Ucraina 27
EE - Estonia 24
BE - Belgio 17
HR - Croazia 14
FI - Finlandia 9
IR - Iran 9
KR - Corea 9
AT - Austria 8
CA - Canada 8
SC - Seychelles 6
CH - Svizzera 5
TR - Turchia 4
LB - Libano 3
NL - Olanda 3
BD - Bangladesh 1
BR - Brasile 1
EC - Ecuador 1
EG - Egitto 1
IL - Israele 1
MK - Macedonia 1
PL - Polonia 1
PT - Portogallo 1
UZ - Uzbekistan 1
Totale 3095
Città #
Southend 418
Chandler 190
Fairfield 180
Woodbridge 92
Houston 91
Wilmington 89
Dong Ket 82
Ann Arbor 78
Ashburn 75
Seattle 75
Princeton 74
Cambridge 67
Lomé 46
Westminster 40
Bologna 37
Nanjing 36
Padova 34
Abeokuta 27
Saint Petersburg 27
Beijing 26
Medford 24
Berlin 18
Jinan 18
Brussels 17
Shenyang 16
Changsha 15
Jiaxing 14
Redwood City 14
Hebei 12
Boardman 11
Nanchang 11
Bremen 10
Helsinki 9
Dearborn 8
Grafing 8
Norwalk 8
San Diego 8
Haikou 7
Tianjin 7
Athens 6
Falls Church 6
Frankfurt am Main 6
Jacksonville 6
Mahé 6
North York 6
Vienna 6
Hangzhou 5
Hefei 5
Zhengzhou 5
Andover 4
Istanbul 4
Riolo Terme 4
Faenza 3
Fuzhou 3
Taglio Di Po 3
Taiyuan 3
Zanjan 3
Brescia 2
Calderara Di Reno 2
Cesena 2
Florence 2
Kunming 2
Las Vegas 2
Lausanne 2
Leawood 2
Milan 2
Moscow 2
New York 2
Portici 2
Rome 2
Sacramento 2
Saint Paul 2
Taizhou 2
Treviso 2
Woubrugge 2
Atlanta 1
Augusta 1
Bern 1
Buffalo 1
Cesenatico 1
Clearwater 1
Costa Mesa 1
Des Moines 1
Frankfurt Am Main 1
Frattamaggiore 1
Fremont 1
Groningen 1
Guangzhou 1
Gurgaon 1
Henderson 1
Jerusalem 1
Kiev 1
Kish 1
Kuban 1
Lanzhou 1
Livorno 1
Macerata 1
Monte Urano 1
Montescudo 1
Ningbo 1
Totale 2164
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 184
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 161
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 136
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 128
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 114
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 114
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 110
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 106
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 105
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 104
null 103
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 99
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 98
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 96
Nuclear inositide signaling in myelodysplastic syndromes. 93
null 93
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 92
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 89
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 88
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 86
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 78
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 78
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 77
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 77
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 76
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 71
null 71
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 68
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 63
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 63
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 62
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 51
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 50
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 45
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 34
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 14
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 9
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 6
Totale 3192
Categoria #
all - tutte 4546
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4546


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201876 0000 00 04 40617
2018/2019239 54109 337 95 20282953
2019/2020971 13535377 92117 10285 132676660
2020/2021520 1002457 2314 1635 50259212
2021/2022778 84115286 7848 1938 3972120131
2022/2023542 7313244115 7467 370 0000
Totale 3192